1 History of Extracorporeal Photopheresis —— 2
1.1 First Clinical Studies Using ECP —— 2
1.2 ECP for Treatment of CTCL and Other Diseases —— 3
1.3 Technical Developments in Use of ECP —— 3
1.4 Current Role of ECP 5

2 Technical Aspects —— 8
2.1 ECP in Children and Adolescents —— 8
2.1.1 Introduction —— 8
2.1.2 ECP Methodology and Instrumentation —— 9
2.1.3 Summary —— 20
2.2 ECP in Patients with Bleeding Risks —— 22
2.2.1 Anticoagulation with Heparin —— 22
2.2.2 Anticoagulation with Acid Citrate Dextrose —— 24
2.2.3 Anticoagulation during ECP in Patients with Bleeding Risks —— 25
2.2.4 Anticoagulation during ECP in Patients with Absolute Contraindications for Heparin Use —— 26
2.2.5 Vienna Experience on ECP with ACD-A —— 26
2.2.6 Recommendations and Conclusions —— 28
2.3 ECP with Central Venous Access —— 30
2.3.1 Arteriovenous Fistulas (AVFs) or Arteriovenous Grafts (AVGs) —— 30
2.3.2 Central Venous Catheters (CVCs) —— 31
2.3.3 Totally Implantable Central Venous Access Systems (Ports) —— 33
2.3.4 Summary/Conclusions —— 35
2.4 New Technical Developments —— 38
2.4.1 Extracorporeal Photopheresis Regulatory Recommendations —— 38
2.4.2 The Closed System’s New Technical Developments —— 39
2.4.3 Conclusions —— 45

3 Mechanisms of Action of ECP —— 48
3.1 Preclinical GVHD Model —— 48
3.1.1 Introduction —— 48
3.1.2 Results —— 48
3.1.3 Discussion —— 53
3.2 Preclinical Hypersensitivity Models —— 59
3.2.1 Introduction —— 59
3.2.2 The Experimental Model —— 59
3.2.3 Characterization of ECP/PUVA-Induced Treg —— 60
3.2.4 Interleukin-10 is a Crucial Mediator —— 60
3.2.5 Other Models and Data Indicating a Role of Treg in ECP —— 62
3.2.6 Conclusion — 62
3.3 Mechanism of Action of ECP – Clinical Evidence — 65
3.3.1 Introduction — 65
3.3.2 Cellular Vaccination Hypothesis — 65
3.3.3 Apoptosis of ECP-Treated Lymphocytes — 66
3.3.4 Direct Effect of ECP on Effector Cells — 67
3.3.5 ECP Modulation of Peripheral Blood Monocytes and Dendritic Cells — 69
3.3.6 Distal Effects on Untreated Lymphocytes in GVHD — 70
3.3.7 Emergence of Regulatory T cell Populations during ECP Treatment — 72
3.3.8 Dysregulation of B Cell Homeostasis and Hallmarks of Improvement in ECP Treatment in GVHD — 73

4 Extracorporeal Photopheresis in Acute Graft-versus-Host Disease — 84
4.1 First-Line Therapy of Acute GVHD — 84
4.1.1 When to Start First-Line Therapy — 84
4.1.2 What First-Line Therapy to Use — 84
4.1.3 Duration of First-Line Therapy and Response — 85
4.1.4 Combination First-Line Therapy — 85
4.2 Predicting GVHD Severity — 86
4.3 Second-line Therapy of Corticosteroid-Refractory Acute GVHD — 86
4.3.1 Defining Steroid-Refractory Acute GVHD — 86
4.3.2 Second-Line Therapy with Immunosuppressive Agents — 86
4.3.3 ECP in Corticosteroid-Refractory Acute GVHD — 87
4.4 Conclusions on the Use of ECP in Acute GVHD — 93

5 Extracorporeal Photopheresis in Chronic Graft-versus-Host Disease — 98
5.1 Results of ECP in Cutaneous Manifestations of Chronic GVHD — 98
5.1.1 Cutaneous Manifestations of Chronic GVHD — 98
5.1.2 Results of Phase II Studies with Non-ECP Therapies for Cutaneous Chronic GVHD — 99
5.1.3 Results of Phase II Studies with ECP Treatment for Cutaneous Chronic GVHD — 99
5.1.4 Results of Two Phase II Randomized, Single-Blind, Multicenter Studies of ECP for Treatment of Cutaneous Chronic GVHD — 100
5.1.5 Summary — 104
5.2 Results of ECP in Extracutaneous Manifestations of Chronic GVHD — 107
5.2.1 Introduction — 107
5.2.2 Liver and Gastrointestinal (GI) GVHD — 107
5.2.3 Ocular and Oral GVHD — 111
5.2.4 Chronic GVHD of the Lungs 114
5.2.5 Summary 116
5.3 ECP in Chronic GVHD: Steroid-Sparing Effect 122
5.3.1 Introduction 122
5.3.2 Corticosteroids and Other Immunosuppressive Agents in Chronic GVHD 122
5.3.3 Overview of ECP in Chronic GVHD and its Steroid-Sparing Effect 124
5.3.4 Conclusions 125
5.4 Prediction of Response to ECP 128
5.4.1 Identification of Biomarkers in Chronic Graft-versus-Host Disease 128
5.4.2 Biomarkers for Prediction of Response to ECP 130
5.4.3 Conclusions 133

6 ECP for the Prevention of Graft-versus-Host Disease 136
6.1 Introduction 136
6.2 Standard GVHD Prevention Strategies 136
6.2.1 Methotrexate 136
6.2.2 Cyclophosphamide 137
6.2.3 Calcineurin Inhibitors 137
6.2.4 Mycophenolate Mofetil 138
6.2.5 Sirolimus 138
6.3 GVHD Prevention with ECP: Potential Mechanism of Action 139
6.3.1 Targeting Dendritic Cells 139
6.3.2 Targeting Regulatory T Cells 141
6.3.3 Targeting Dendritic Cells and Regulatory T Cells 143
6.4 Extracorporeal Photopheresis during HCT Preparative Regimens 144
6.5 ECP for Prevention of Solid Organ Rejection 145
6.6 ECP for GVHD Prevention: Tolerogenic DC and Treg Induction 146
6.7 Conclusions 147

7 ECP in Cutaneous T Cell Lymphoma 152
7.1 ECP for Treatment of CTCL 152
7.1.1 Treatment Schedule 154
7.1.2 Recommendations 155
7.2 Predictors of Response 158
7.3 Adjuvant Therapy 158
7.4 Monitoring during ECP Therapy 158
7.5 Conclusion 159

8 ECP in Scleroderma and Other Skin Diseases 164
8.1 Systemic Sclerosis 164
8.1.1 ECP in Systemic Sclerosis 164
8.2 ECP in Localized Scleroderma/Morphea —— 166
8.3 ECP in Autoimmune Bullous Diseases —— 167
8.4 Atopic Dermatitis —— 167

9 ECP in Crohn’s Disease —— 170
9.1 Results on ECP in Crohn’s Disease —— 170
9.2 Conclusions —— 171

10 Extracorporeal Photopheresis after Solid Organ/
Tissue Transplantation —— 174
10.1 Prevention and Treatment of Solid Organ Transplant Rejection —— 174
10.1.1 Introduction —— 174
10.1.2 Immune Mechanisms of Acute and Chronic Allograft Rejection —— 175
10.1.3 Potential Mechanisms of Action of Photopheresis in the Treatment of Allograft Rejection —— 177
10.1.4 ECP in Lung Transplantation —— 179
10.1.5 ECP in Cardiac Transplantation —— 182
10.1.6 ECP in Renal Transplantation —— 185
10.2 ECP after Facial Transplantation —— 191
10.2.1 Introduction —— 191
10.2.2 Immunosuppression in Organ and Tissue Transplantation —— 191
10.2.3 Case Description —— 192
10.2.4 Conclusions —— 194

11 ECP in Diabetes Mellitus —— 200
11.1 Introduction —— 200
11.2 Prospective, Placebo-Controlled Clinical Study on Use of ECP —— 201
11.3 Results —— 202
11.3.1 Discussion of Study Results —— 202
11.4 Conclusions —— 205

12 Side Effects of Extracorporeal Photopheresis —— 208
12.1 Side Effects Concerning the Apheresis Procedure —— 208
12.2 Side Effects Concerning 8-Methoxypsoralen —— 209
12.3 Miscellaneous —— 210

13 Summary —— 214